D. Boral Capital, under the guidance of analyst Jason Kolbert, has issued its latest report on CollPlant Biotechnologies (CLGN, Financial) dated May 30, 2025. The firm maintains its stance on the stock with a 'Buy' rating. Previously, the stock was also rated as 'Buy', indicating continued confidence in its prospects.
The price target for CollPlant Biotechnologies (CLGN, Financial) is maintained at $12.00, with no change from the prior target set by the firm. This consistency suggests that the analyst sees stability in the stock's potential value in the market. Despite no percentage change in the price target, D. Boral Capital remains optimistic about the company's future performance.
CollPlant Biotechnologies (CLGN, Financial), listed on the NASDAQ, continues to be under watch by investors and analysts alike as it operates in the biotech sector. The company's current valuation by D. Boral Capital indicates a growing interest in its innovative solutions and market positioning.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for CollPlant Biotechnologies Ltd (CLGN, Financial) is $14.00 with a high estimate of $14.00 and a low estimate of $14.00. The average target implies an upside of 348.72% from the current price of $3.12. More detailed estimate data can be found on the CollPlant Biotechnologies Ltd (CLGN) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, CollPlant Biotechnologies Ltd's (CLGN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CollPlant Biotechnologies Ltd (CLGN, Financial) in one year is $12.48, suggesting a upside of 300% from the current price of $3.12. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CollPlant Biotechnologies Ltd (CLGN) Summary page.
